Back

De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer

Zhang, H.; Yu, Q.; Santana-Codina, N.; Poupault, C.; Campos, C.; Qin, X.; Padhye, A.; Sindoni, N.; Kuljanin, M.; Wang, J.; Dorman, M. J.; Aguirre, A. J.; Dougan, S. K.; Sarosiek, K. A.; Mancias, J. D.

2024-05-21 cancer biology
10.1101/2024.05.17.594738 bioRxiv
Show abstract

Oncogenic KRAS, the genetic driver of 90% of pancreatic adenocarcinoma (PDAC), induces a metabolic rewiring characterized, in part, by dependency on de novo pyrimidine biosynthesis. Pharmacologic inhibition of dihydroorotate dehydrogenase (DHODH), an enzyme in the de novo pyrimidine synthesis pathway, delays pancreatic tumor growth in vivo; however, limited monotherapy efficacy suggests compensatory pathways and that combinatorial strategies are required for enhanced efficacy. Here, we use an integrated metabolomic, quantitative temporal proteomic and in vitro and in vivo DHODH inhibitor anchored CRISPR/Cas9 genetic screening approach to identify compensatory pathways to DHODH inhibition (DHODHi) and targets for combination strategies. We demonstrate that DHODHi alters the apoptotic regulatory proteome thereby enhancing sensitivity to inhibitors of the anti-apoptotic BCL2L1 (BCL-XL) protein. Combinatorial regimens with DHODH and BCL-XL inhibition synergistically induce apoptosis in PDAC cell lines and patient-derived PDAC organoids. In vivo DHODH inhibition with Brequinar and BCL-XL degradation with DT2216, a proteolysis targeting chimera (PROTAC), significantly inhibits the growth of PDAC tumors. Our data defines mechanisms of adaptation to DHODH inhibition and identifies a combination therapy strategy in PDAC.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 10%
18.3%
Similar papers in this journal
2
Cancer Research
● 130 papers in training set
Top 0.5%
6.2%
Similar papers in this journal
3
Cancer Discovery
● 66 papers in training set
Top 0.5%
5.1%
Similar papers in this journal
4
Science Advances
● 1243 papers in training set
Top 6%
4.8%
Similar papers in this journal
5
Nature Cancer
○ 39 papers in training set
Top 0.4%
4.3%
Similar papers in this journal
6
Cell Death & Disease
147 papers in training set
Top 0.9%
3.2%
7
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 19%
2.7%
8
Cell Reports Medicine
○ 153 papers in training set
Top 1%
2.4%
9
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.5%
2.4%
10
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.3%
2.4%
50% of probability mass above
11
Cell Reports
○ 1498 papers in training set
Top 15%
2.4%
12
Communications Biology
○ 993 papers in training set
Top 9%
2.4%
13
ACS Chemical Biology
● 167 papers in training set
Top 1%
2.1%
14
eLife
● 5828 papers in training set
Top 46%
2.1%
15
Cell Chemical Biology
○ 94 papers in training set
Top 0.8%
1.7%
16
Scientific Reports
○ 3612 papers in training set
Top 57%
1.5%
17
Gastroenterology
○ 42 papers in training set
Top 0.7%
1.5%
18
iScience
○ 1154 papers in training set
Top 22%
1.4%
19
Cancer Research Communications
● 51 papers in training set
Top 1%
1.1%
20
JCI Insight
● 277 papers in training set
Top 6%
1.1%
21
British Journal of Cancer
○ 49 papers in training set
Top 1%
1.1%
22
Oncogene
○ 85 papers in training set
Top 1%
1.1%
23
Clinical Cancer Research
● 64 papers in training set
Top 2%
1.1%
24
eBioMedicine
○ 183 papers in training set
Top 5%
1.0%
25
Journal of Clinical Investigation
● 179 papers in training set
Top 5%
1.0%
26
Nature Biomedical Engineering
○ 47 papers in training set
Top 2%
1.0%
27
Cancer Cell
○ 42 papers in training set
Top 1%
0.8%
28
Molecular Therapy Oncology
○ 10 papers in training set
Top 0.2%
0.8%
29
Cell Death Discovery
○ 58 papers in training set
Top 1%
0.8%
30
Cancer Letters
○ 35 papers in training set
Top 1%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.